Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution